Skip to content
drillr.ai
Sign up

ZTS

Zoetis Inc.

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US

$75.81
−0.63%
Ask drillr

  • Sep 2, 2026, 23:59 UTC

    The U.S. Food and Drug Administration published in the Federal Register three Emergency Use Authorizations for animal drugs to treat or prevent New World screwworm, including the first injectable product listing deer, issued to Zoetis, Felix Pharmaceuticals, and Alberta Vet Labs.

    Source:

  • Aug 13, 2026, 17:11 UTC

    Zoetis received emergency use authorization for its drug to treat screwworm, causing its stock price to rise.

    Source:

  • Aug 11, 2026, 05:21 UTC

    Zoetis Inc.'s stock price hit a new 52-week low during mid-day trading on Monday after Piper Sandler lowered its price target from $90.00 to $80.00.

    Source:

  • Aug 6, 2026, 11:32 UTC

    Zoetis announced a quarterly dividend of $0.53 per share, an increase of $0.03 from the prior year's quarter.

    Source:

  • Aug 6, 2026, 11:00 UTC

    Zoetis Inc. reported its financial results for the second quarter of 2026, with revenue of $2.5 billion, flat compared to the same quarter of 2025, and net income of $691 million, or $1.65 per diluted share, down 5% on a reported basis.

    Source:

  • Jul 22, 2026, 11:30 UTC

    Zoetis Inc. launched Portela (relfovetmab) in Canada and the European Union.

    Source:

  • Jul 16, 2026, 14:09 UTC

    A securities class action lawsuit has been filed against Zoetis Inc. in connection with alleged misrepresentations about its companion animal growth narrative.

    Source:

  • Jul 15, 2026, 12:30 UTC

    Zoetis launched Lenivia (izenivetmab injection) in Canada and the European Union.

    Source:

  • Jul 14, 2026, 13:00 UTC

    Zoetis Inc. announced an agreement to acquire VitalRADS, a veterinary teleradiology services platform.

    Source:

  • Jul 7, 2026, 11:00 UTC

    The European Commission granted marketing authorization to Zoetis for Poulvac Procerta HVT-ND, a recombinant vector vaccine for chickens against Newcastle disease and Marek's disease.

    Source:

  • Jun 15, 2026, 14:31 UTC

    Anterra Capital reached a $100 million first close for Fund III, targeting $200 million, with backing from Rabobank, Novo Holdings, and Zoetis among others.

    Source:

  • Jun 3, 2026, 06:57 UTC

    A class action lawsuit was filed against Zoetis Inc. for alleged securities law violations.

    Source: